Invesaro

Stocks Health care AZN

NYSE · Health care

Astrazeneca PLC (AZN)

Astrazeneca PLC reported revenue of $58.7B in fiscal 2025, up 8.6% from a year earlier. Net income was $10.2B, a net margin of 17.4%. Operating cash flow minus capital spending left $11.8B of free cash flow in fiscal 2025. At December 31, 2025 it held $5.7B in cash against $29.6B of debt.

Price
$166.58
+1.23% on the day · September 25, 2026
52-week range $146.66 to $212.71
Market cap
$258.3B
Revenue (FY2025)
$58.7B
+8.6% year on year
Net margin
17.4%

What Astrazeneca PLC does

AstraZeneca is a biopharmaceutical company that discovers, develops, and manufactures prescription medicines. Its treatments focus on oncology, cardiovascular diseases, renal conditions, and respiratory ailments. Its products are sold to hospitals, healthcare providers, and pharmacies globally. Its shares trade on NYSE under the ticker AZN.

Revenue and profit by year

Revenue
FY18: $22.1B $22.1B FY18FY19: $24.4B $24.4B FY19FY20: $26.6B $26.6B FY20FY21: $37.4B $37.4B FY21FY22: $44.4B $44.4B FY22FY23: $45.8B $45.8B FY23FY24: $54.1B $54.1B FY24FY25: $58.7B $58.7B FY25
Net income
FY18: $2.2B $2.2B FY18FY19: $1.3B $1.3B FY19FY20: $3.2B $3.2B FY20FY21: $112M $112M FY21FY22: $3.3B $3.3B FY22FY23: $6B $6B FY23FY24: $7B $7B FY24FY25: $10.2B $10.2B FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$58.7B$13.7B$10.2B$6.54$11.8B
2024$54.1B$10B$7B$4.50$9.9B
2023$45.8B$8.2B$6B$3.81$9B
2022$44.4B$3.8B$3.3B$2.11$8.7B
2021$37.4B$1.1B$112M$0.08$4.9B
2020$26.6B$5.2B$3.2B$2.44$3.8B

Latest SEC filings

What Astrazeneca PLC has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 23, 2026
    Foreign issuer update 6-K
  2. September 21, 2026
    Foreign issuer update 6-K
  3. September 21, 2026
    Foreign issuer update 6-K
  4. September 18, 2026
    Foreign issuer update 6-K
  5. September 15, 2026
    Foreign issuer update 6-K
  6. September 15, 2026
    Foreign issuer update 6-K
  7. September 14, 2026
    Foreign issuer update 6-K
  8. September 8, 2026
    Foreign issuer update 6-K
  9. September 8, 2026
    Foreign issuer update 6-K
  10. September 1, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 11, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about AZN

What does Astrazeneca PLC do?

AstraZeneca is a biopharmaceutical company that discovers, develops, and manufactures prescription medicines. Its treatments focus on oncology, cardiovascular diseases, renal conditions, and respiratory ailments. Its products are sold to hospitals, healthcare providers, and pharmacies globally. Its shares trade on NYSE under the ticker AZN.

Is Astrazeneca PLC profitable?

Yes. In fiscal 2025 it reported net income of $10.2B on revenue of $58.7B, a net margin of 17.4%.

How much revenue does Astrazeneca PLC make?

In fiscal 2025 Astrazeneca PLC reported revenue of $58.7B. That is 8.6% more than a year earlier.

When did Astrazeneca PLC last report?

Its newest filing of any kind is the foreign issuer update from September 23, 2026.

Similar companies

JNJ
Johnson & Johnson
LLY
ELI LILLY & Co
MRK
Merck & Co., Inc.
PFE
Pfizer Inc
ABBV
AbbVie Inc.
BMY
Bristol Myers Squibb Co

Follow AZN

Get an email when Astrazeneca PLC files with the SEC: results, executive changes, material agreements and annual reports.

Follow AZN: get an email when it files

Where the numbers come from

Financial figures are the values Astrazeneca PLC tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.